National Institute for Health and Clinical Excellence (NICE)
New draft guideline to help reduce health inequalities in people experiencing homelessness
NICE and the Centre for Homelessness Impact (CHI) have jointly published a new draft guideline to increase the access people experiencing homelessness have to health and social care services and improve their health outcomes.
People experiencing homelessness face significant health inequalities and poorer health outcomes than the rest of the population. Mortality among people experiencing homelessness is around ten times higher than the rest of the population and life expectancy is around 30 years less. Yet, many of these deaths are from preventable causes. The homeless population face barriers to accessing health and social care services including stigma and discrimination, a lack of trusted contacts, and rigid eligibility criteria for accessing services.
The draft guideline (published 6 October) covers people aged over 16 experiencing homelessness, including people sleeping rough, staying in temporary accommodation or ‘sofa surfing’ with family and friends.
The draft guideline highlights that more effort and targeted approaches are often needed to ensure that people experiencing homelessness have access to the same standard of health and social care as the general population.
It recommends that care should be delivered via specialist multidisciplinary teams which span all sectors of care and be tailored to meet local needs. This care should encompass the physical health needs, mental health and psychological needs, drug and recovery needs, and social care needs of people experiencing homelessness.
Dr Paul Chrisp, director of the NICE Centre for Guidelines, yesterday said:
“People experiencing homelessness face significant barriers to accessing health and social care compared with the general population, which results in huge health inequalities.
“’Homelessness’ is a broad term as outlined by our draft guideline and does not simply refer to a person sleeping rough on the streets. By better understanding which people are experiencing homelessness and what their specific needs are, health and social care professionals will be better able to help them access the services they require.
“We’re pleased to publish this draft guideline, developed in partnership with the CHI and PHE, and hope the recommendations will help improve outcomes for people experiencing homelessness in line with NHS Long Term Plan.”
Dr Lígia Teixeira, chief executive of the Centre for Homelessness Impact, yesterday said:
"The quality of services offered to people who are most excluded from society is too often far behind that offered to the general population.
"People who experience homelessness often have poorer health, especially mental health, and this guideline is an important step towards making health and social care services more accessible to them. It is very important to ensure that their needs as individuals are met and the guideline shows how this can be done sensitively and flexibly."
The draft recommendations suggest offering mobile outreach services with flexible opening and appointment times, drop-in services, and help with transport would reduce barriers homeless people experience accessing health and care services.
They should not be penalised for missing appointments, for example by being discharged from the service. Peer supporters and advocates can help the person attend appointments or re-engage with care after missing appointments.
The draft guideline recommends that long-term engagement should be planned to help people who struggle to engage with services. Practitioners should take time to build a relationship of trust with the person, particularly when they first engage with services.
NICE and CHI worked with Public Health England (PHE), which has been succeeded by the Office for Health Improvement and Disparities (OHID), to develop this draft guideline.
The draft guideline will be out for consultation until 3 November and can be read here.
Latest News from
National Institute for Health and Clinical Excellence (NICE)
NICE updates managing COVID guideline with new monoclonal antibody recommendations06/10/2021 11:15:00
NICE has updated its managing COVID-19 guideline to include new recommendations on using monoclonal antibodies to treat COVID-19 patients in hospital.
NICE recommends first treatment in two decades for sickle cell disease05/10/2021 11:15:00
Hundreds of people will be eligible for a new treatment for sickle cell disease following draft guidance published today (5 October).
People with advanced or metastatic urothelial cancer to get life-extending treatment01/10/2021 11:15:00
Around 130 people per year with untreated locally advanced or metastatic urothelial cancer will be eligible for a new life-extending treatment after NICE published final draft guidance yesterday (30 September 2021) recommending atezolizumab.
Update on the NICE ME/CFS guideline roundtable discussion22/09/2021 09:10:00
The roundtable meeting to discuss the updated guideline on the diagnosis and management of ME/CFS will be held on October 18th in London. It is being convened after publication of the guideline was paused when issues were raised by some professional groups during the pre-publication period
NICE and PHE recommend all employers give mental health training for managers17/09/2021 11:10:00
All managers should be given the skills to support employees with mental health issues, NICE and PHE have said in new guidance.
NICE recommends treatment for people with juvenile idiopathic arthritis10/09/2021 11:15:00
NICE yesterday (9 September 2021) published final draft guidance which recommends tofacitinib (also known as Xeljanz and made by Pfizer) as an option for treating active polyarticular juvenile arthritis and juvenile psoriatic arthritis in people 2 years and older.
Professor Gillian Leng to retire from NICE09/09/2021 14:15:00
Professor Leng has spent more than 20 years working at NICE.
NICE draft guidance recommends apalutamide for treating prostate cancer08/09/2021 12:20:00
NICE has today (8 September 2021) published final draft guidance which now recommends apalutamide (also called Erleada and made by Janssen) plus androgen deprivation therapy for treating prostate cancer in adults